Schrodinger, Inc.

SDGR

$90.89

+178.84% (1 year change)

Avg closing price

Price range

Market Cap

$4.5 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

-

Total revenue in the last quarter.

Net Income

-

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

$0.00

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

0.0x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

-

Earnings before interest expenses and taxes in the last quarter.

Employees

0

The number of full time employees.

Revenue & Earnings

Balance Sheet

Schrodinger, Inc.

News

Why the success of model portfolios and the paradox of Schrodinger’s cat have a lot in common

Why the success of model portfolios and the paradox of Schrodinger’s cat have a lot in common

Why the success of model portfolios and the paradox of Schrodinger’s cat have a lot in common Submitted 10/12/2020 - 1:48pm By Allan Lane, Algo-Chain – According to a recent article in the Wall Str...

Wealth Adviser Wealth Adviser, about 1 month ago
Schrödinger Presents Data from Its MALT1 Inhibitor Program at the American Society of Hematology (ASH) 2020 Annual Meeting

Schrödinger Presents Data from Its MALT1 Inhibitor Program at the American Society of Hematology (ASH) 2020 Annual Meeting

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, presented preclinical data from...

Business Wire Business Wire, about 1 month ago
Schrödinger Climbs on $2.7 Billion Bristol-Myers Squibb Deal

Schrödinger Climbs on $2.7 Billion Bristol-Myers Squibb Deal

Bristol-Myers Squibb will pay Schrodinger $55 million up front, plus up to $2.7 billion in milestone payments, in a drug-development deal.

Yahoo Finance Yahoo Finance, about 2 months ago